GRFS · Healthcare · $6.2B
$7.22-1.30%
What's this stock's score right now?
See its score for free — revenue and money flow, graded on one standard.
Quarterly Financials
9/'26
6/'26 vs prev quarter
Among 19 Drug Manufacturers - General peers
Quarterly Revenue Growth
“바이오파마 매출이 전년 동기 대비 5.4% 성장하며 그룹 전체 성장(2.6%)을 이끌었어요 — 특히 피하주사형 면역글로불린 XEMBIFY가 2분”
In the company's words · 2026 2분기 earnings call